SECTOR: HEALTHCARE
POLAREAN IMAGING (POLX.L)
SECTOR – HEALTHCARE
RATING – CORP*
MARKET CAP – £12.3m
CURRENT PRICE – 17p#
ANALYST – VADIM ALEXANDRE
Year-end Dec
2017A
Revenue ($m)
1.24
EBITDA ($m)
(3.55)
Adj. pre-tax Profit ($m)
(3.96)
Net Cash/(Debt) ($m)
(0.14)
No forecasts provided
SOURCE: Northland Capital Partners Limited estimates.*Northland Capital Partners Limited provides acts as Nomad and Broker to Polarean Imaging Ltd. and therefore this information should be viewed as a Marketing Communication.
From yesterday: Completion of US$1 million placing
NORTHLAND VIEW
- Polarean Imaging announced the successful completion of a placing to raise £0.8 million (US$1.064 million) (before expenses).
- A total of 5 million shares have been conditionally placed with new and existing investors at a price of 16p/share. The shares will represent 6.4% of the Company's issued Ordinary Share capital.
The Placing, conducted by Northland, was in response to strong demand from institutional and EIS/VCT investors and the net proceeds will be used to further support the FDA Phase III clinical trials and improvements to the Company's polarisers.
COMPANY DESCRIPTION
Polarean Imaging is a healthcare technology company with a proprietary drug-device combination in late-stage clinical trials.